Amitriptyline: Independent Evidence on Pain, Migraine, IBS, Risks & Withdrawal

Table of contents

• Evidence summary
• What amitriptyline is
• How it works
• What it is prescribed for
• What works and what does not
• Benefits by claim
• Risks and all side effects
• All interactions
• Who should avoid amitriptyline
• Dosage and how to take it
• Follow the money: who makes it and who funded the evidence
• Related research
• Frequently asked questions
• Sources and funding notes

Evidence summary

Independent evidence and credibility scorecard

Independence tier: 1 = no money from anyone selling the product; 4 = seller-funded. Credibility: A (highest) to D.

What amitriptyline is

Amitriptyline is a tricyclic antidepressant (TCA). Its ATC code is N06AA09 and it is classed as a "non-selective monoamine reuptake inhibitor" (UK SmPC). Merck & Co developed it in the United States. It started as an attempt at an antipsychotic, and Merck commissioned the psychiatrist Frank Ayd, who tested it as an antidepressant instead. The US FDA approved it on 7 April 1961 under the brand name Elavil. Merck and Hoffmann-La Roche then co-marketed it worldwide (as Elavil and Tryptizol), and Roche also held European rights under the name Saroten (López-Muñoz et al., World J Psychiatry 2022). The original Elavil applications (NDA 012703 for tablets and NDA 012704 for injection) are now held by AstraZeneca and listed as discontinued (Drugs@FDA).

Today amitriptyline is a fully generic, prescription-only medicine in both the UK and the US. In the UK it comes as 10 mg, 25 mg and 50 mg tablets and as an oral liquid (NHS). The FDA database lists 19 active single-ingredient US generic approvals, held by companies including Accord, Aurobindo, Mylan, Sandoz, Sun Pharma, Unichem and Zydus (openFDA Drugs@FDA data, queried 26 September 2026). It is one of only two tricyclics on the WHO Model List of Essential Medicines, alongside clomipramine (Cipriani et al. 2018). The WHO mhGAP guideline names it as the listed tricyclic for depression (WHO mhGAP 2023).

How it works

Amitriptyline blocks the reuptake of two chemical messengers, noradrenaline and serotonin, at nerve endings. This is thought to underlie its antidepressant effect. It also blocks sodium, potassium and NMDA ion channels in the brain and spinal cord. The UK product information says these extra actions are involved in its effects on nerve pain, tension-type headache and migraine, and that "the pain-reducing effect of amitriptyline is not linked to its anti-depressive properties" (UK SmPC). This is why pain doses are much lower than depression doses. The NHS says that taking it for pain "will not have the same effect as taking it for depression" (NHS). The FDA label is more cautious and states that its mechanism "in man is not known" (FDA label).

It also binds strongly to muscarinic (acetylcholine) and histamine H1 receptors. This explains most of its everyday side effects: dry mouth, constipation, blurred vision and urinary retention from the anticholinergic action, and sleepiness from the antihistamine action (UK SmPC). The liver breaks it down, mainly through the enzymes CYP2C19 and CYP2D6, into nortriptyline, which is itself an active antidepressant. Its elimination half-life is about 25 hours, and steady levels are reached within about a week (UK SmPC). Both enzymes vary between people. About 7–10% of white people are CYP2D6 "poor metabolisers", who can have up to 8 times higher blood levels of a tricyclic at usual doses (FDA label). The NIH-funded CPIC pharmacogenetics guideline advises avoiding amitriptyline in CYP2D6 poor metabolisers. If it is still needed, CPIC suggests starting at half the usual dose. It notes that these dose rules apply to the higher starting doses used in depression rather than to low-dose pain treatment (Hicks et al., CPIC 2016 update).

What it is prescribed for

The UK licences come from the UK SmPC (revised April 2026). The US licence comes from the FDA label. Off-label means the prescriber takes responsibility for using the medicine outside its licence. It does not mean the use is unsafe or unsupported.

What works and what does not

Benefits by claim

Irritable bowel syndrome: the strongest new evidence

ATLANTIS is the largest trial of a tricyclic antidepressant in IBS ever conducted, in the authors' words. It enrolled 463 adults with IBS whose symptoms had continued despite diet changes and first-line medicines. Patients started at 10 mg at night and could adjust their own dose up to 30 mg, guided by a written titration sheet. At 6 months the IBS Severity Scoring System favoured amitriptyline by 27.0 points (95% CI −46.9 to −7.1; p=0.0079) (Ford et al., Lancet 2023). Scores improved by an average of 99 points on amitriptyline and 69 points on placebo. Sixty-one per cent of the amitriptyline group reported relief of their IBS symptoms, against 45% on placebo (NIHR Evidence). The odds ratio for relief was 1.78 (95% CI 1.19 to 2.66) (HTA report).

Honest reading: this is a well-run, publicly funded, double-blind trial, and the benefit is real. Two caveats matter. First, most of the improvement also happened on placebo (69 of the 99 points). Second, the trial's own report defined a 35-point between-group difference as the minimum clinically important difference. The average result, 27 points, fell short of that, although the confidence interval reaches past it (HTA report). The key secondary outcome, global relief, was clearly positive. Amitriptyline did not change anxiety, depression or work and social adjustment scores. This fits the idea that the gut benefit is not simply an antidepressant effect. Earlier meta-analyses pointed the same way. In a network meta-analysis, tricyclics ranked second for global IBS symptoms (RR of symptoms not improving 0.66, 95% CI 0.53–0.83). They ranked first for abdominal pain (RR 0.53), but that result came from only four trials with 92 patients, and only 13 of the 51 trials were at low risk of bias (Black et al., Lancet Gastroenterol Hepatol 2020). A 2019 meta-analysis found antidepressants overall reduced the chance of IBS symptoms not improving (RR 0.66, 95% CI 0.57–0.76) (Ford et al., Am J Gastroenterol 2019). In a post-hoc (after-the-fact) analysis of ATLANTIS, the effect was larger in people aged 50 and over (mean difference −46.5 points). Exploratory findings like this need confirming before they guide treatment (Wright-Hughes et al., Gut 2025).

Depression: high efficacy, low tolerability, old evidence

In the Cipriani 2018 network meta-analysis (522 trials, 116,477 participants), every antidepressant beat placebo. Response odds ratios ranged from 2.13 (95% CrI 1.89–2.41) for amitriptyline down to 1.37 for reboxetine. In head-to-head trials, amitriptyline was among the more effective drugs. It was also among the drugs with "the highest dropout rates", alongside clomipramine, duloxetine, fluvoxamine, reboxetine, trazodone and venlafaxine (ORs 1.30–2.32) (Cipriani et al., Lancet 2018). The authors flag two further limits. Certainty was low to very low for most amitriptyline comparisons. And "smaller and older studies presented larger effects of the active interventions versus placebo (in particular for amitriptyline...)". The top ranking may therefore partly reflect the older trial era rather than a truly larger effect. The NHS gives patients a plainer summary: amitriptyline "does not work any better or worse than other antidepressants", but some people find the side effects a problem (NHS). For the broader debate on how much antidepressants help beyond placebo, see our stress, anxiety and depression guide.

Neuropathic pain: first-line in guidelines, thin in trials

The Cochrane review (17 studies, 1,342 participants, seven nerve-pain conditions) found "no first-tier or second-tier evidence for amitriptyline in treating any neuropathic pain condition". Only two of seven studies reporting useful data showed a significant benefit, and the evidence was very low quality. The authors did not conclude that it fails. They wrote that there is "no good evidence of a lack of effect; rather our concern should be of overestimation of treatment effect". They added that it should remain part of treatment, "but only a minority of people will achieve satisfactory pain relief" (Moore et al., Cochrane 2015).

The pooled class-level picture is more favourable. The 2025 NeuPSIG meta-analysis (313 trials, 48,789 adults) estimated a number needed to treat of 4.6 (95% CI 3.2–7.7) for tricyclic antidepressants, rated moderate certainty. That compares with 7.4 for SNRIs such as duloxetine and 8.9 for gabapentin and pregabalin. On that basis it issued a strong first-line recommendation for all three classes (Soliman et al., Lancet Neurol 2025). The earlier 2015 NeuPSIG review also noted that "cost was lower for tricyclic antidepressants" (Finnerup et al., Lancet Neurol 2015). These are class estimates, not amitriptyline-only ones. The authors describe outcomes across all treatments as "modest".

Fibromyalgia and chronic primary pain

In fibromyalgia, the Cochrane review found only third-tier evidence (9 studies, 649 participants, doses 25–50 mg). The risk ratio for at least 50% pain relief was 3.0 and the NNT was 4.1, both rated very low quality. There were no consistent effects on fatigue, sleep or quality of life (Moore et al., Cochrane 2019). A 2025 overview of Cochrane reviews concluded that the amitriptyline evidence was "subject to publication bias". It rated duloxetine, milnacipran and pregabalin as having better evidence, with about 1 in 10 patients getting substantial relief (Moore et al., Rheumatology 2025). A network meta-analysis of 36 studies found a different pattern. Amitriptyline was associated with better sleep (SMD −0.97), less fatigue and better quality of life than placebo, and it was the only drug without a higher dropout rate than placebo (OR 0.78, 95% CrI 0.31–1.66) (Farag et al., JAMA Netw Open 2022). NICE allows amitriptyline, among other antidepressants, to be considered for chronic primary pain (NICE NG193).

Migraine and tension-type headache

For adult migraine, NICE's 2025 amendment keeps amitriptyline alongside propranolol and topiramate as a preventive option (NICE CG150). The 2026 AAN and American Headache Society systematic review (217 studies) put amitriptyline among several oral drugs with "low-confidence evidence suggesting possible benefit" for episodic migraine. By contrast, propranolol and topiramate had moderate-confidence evidence, and some CGRP antibodies had high-confidence evidence (Pringsheim et al., Neurology 2026). In children and teenagers, the NIH-funded CHAMP trial was stopped for futility. Fifty-two per cent improved on amitriptyline, 55% on topiramate and 61% on placebo (Powers et al., NEJM 2017). For chronic tension-type headache, a 2026 network meta-analysis ranked amitriptyline 100 mg highest for reducing headache days. The certainty was low to very low, the risk of bias was high, and adverse events were more common than on placebo (Tao et al., Ann Med 2026).

Sleep and other uses

Amitriptyline is often prescribed for sleep, and the NHS notes that "many people sleep better while they're taking amitriptyline" (NHS). But the Cochrane review of antidepressants for insomnia found "no evidence for amitriptyline (despite common use in clinical practice)". It found only low-dose doxepin and trazodone trials showing small short-term gains (Everitt et al., Cochrane 2018). For chronic low back pain, an Australian government-funded trial found 25 mg did not significantly reduce pain at 6 months compared with an active placebo. The authors suggested it "may be worth considering" only if the alternative is an opioid (Urquhart et al., JAMA Intern Med 2018).

Risks and all side effects

At pain doses, "the common side effects tend to be milder and go away within a few days" (NHS). Trial data show that side effects are still very common. In the neuropathic pain trials, 55% of people on amitriptyline had at least one adverse event, against 36% on placebo (number needed to harm 5.2) (Cochrane 2015). In the fibromyalgia trials the figures were 78% vs 47% (NNH 3.3) (Cochrane 2019). In ATLANTIS, 12.9% withdrew because of adverse events on amitriptyline vs 8.7% on placebo, and most events were mild (HTA report).

Boxed warning (FDA)

The US label carries the class boxed warning. In short-term trials, antidepressants "increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults". No increase was seen in adults over 24, and risk fell in adults 65 and over. Pooled across drugs, the difference from placebo was 14 extra cases per 1,000 patients under 18 and 5 extra per 1,000 aged 18–24. There was 1 fewer case per 1,000 aged 25–64 and 6 fewer per 1,000 aged 65 and over. Everyone starting treatment should be watched closely for worsening, especially in the first few months and after any dose change. The label also asks prescribers to write prescriptions "for the smallest quantity of tablets consistent with good patient management, in order to reduce the risk of overdose" (FDA label).

Withdrawal (discontinuation) symptoms

Amitriptyline is not addictive, but stopping suddenly can cause withdrawal effects (NHS). The FDA label says that after long use, abrupt stopping "may produce nausea, headache, and malaise". Even gradual reduction can bring "transient symptoms including irritability, restlessness, and dream and sleep disturbance" within two weeks. Rarely, mania or hypomania appears 2–7 days after stopping (FDA label). NICE's 2022 depression guideline confirms that withdrawal symptoms occur with tricyclics as well as newer antidepressants (NICE NG222).

Overdose: why this drug needs extra care

In England and Wales from 2000 to 2006, amitriptyline was involved in 395 single-antidepressant deaths recorded as suicide or undetermined intent. Only dosulepin was involved in more (Hawton et al., BJPsych 2010). Compared with non-fatal self-poisonings, the case-fatality rate ratio was 13.8 for tricyclics, 2.5 for venlafaxine, 1.9 for mirtazapine and 0.5 for SSRIs. Within the tricyclic group, dosulepin and doxepin were two to three times more toxic than amitriptyline. This study was funded by the NIHR. The FDA label describes overdose as causing "cardiac dysrhythmias, severe hypotension, convulsions, and CNS depression, including coma". It warns that symptoms "develop rapidly", so hospital monitoring is needed at once (FDA label). This risk applies whatever the reason for prescribing. A tablet supply meant for pain is just as dangerous in overdose as one meant for depression.

All interactions

Interaction sources: UK SmPC section 4.5, FDA label, NHS interactions page, NHS common questions, and MHRA Drug Safety Update on tapentadol. Our St John's wort review covers that herb's interactions in detail.

Who should avoid amitriptyline

Must not take it (UK contraindications): people with a known allergy to amitriptyline, a recent heart attack, any degree of heart block or heart rhythm disorder, coronary artery insufficiency or severe liver disease. It must not be taken with MAOIs or given to children under 6 (UK SmPC). The US label adds cisapride and the acute recovery phase after a heart attack (FDA label).

Needs extra caution: people with epilepsy (or having ECT), glaucoma, trouble passing urine or an enlarged prostate, heart problems, liver or kidney problems, diabetes, an overactive thyroid, bipolar disorder or psychosis, or thoughts of self-harm (NHS, UK SmPC). Before starting any antidepressant, the FDA label advises screening for bipolar disorder because it can trigger mania (FDA label). NICE advises against routinely starting a tricyclic (except lofepramine) in anyone at significant risk of suicide (NICE NG222).

Older adults (65+): the 2023 AGS Beers Criteria list amitriptyline among "antidepressants with strong anticholinergic activity". They describe these drugs as "highly anticholinergic, sedating, and cause orthostatic hypotension" and recommend "Avoid" (quality of evidence: high; strength: strong). Separately, Beers says to avoid tertiary tricyclics in people with a history of fainting (AGS Beers 2023). The FDA label says older patients are "particularly sensitive" to anticholinergic effects and "may be at increased risk for falls" (FDA label). In a nested case-control study of 284,343 people in English general practice, the highest cumulative exposure to anticholinergic antidepressants was associated with an adjusted odds ratio for dementia of 1.29 (95% CI 1.24–1.34). This is an association, not proof of cause (Coupland et al., JAMA Intern Med 2019). Beers applies to US practice and supports shared decision-making; it does not ban the drug. A low dose may still be judged reasonable after an individual review.

Pregnancy and breastfeeding: the NHS says amitriptyline "can be taken during pregnancy and is not thought to be harmful to your baby", although paracetamol is usually tried first for pain. Babies exposed near birth are monitored for temporary withdrawal effects (NHS pain page, NHS depression page). The UK product information is more cautious. It calls the human data "limited", says the drug is "not recommended during pregnancy unless clearly necessary", and lists possible newborn withdrawal signs (UK SmPC). Only very small amounts pass into breast milk. The NHS says it can be used while breastfeeding a healthy baby, but not to share a bed with the baby (NHS). Anyone who is pregnant or planning pregnancy should make this decision with their prescriber.

Children and young people: UK product information says it should not be used under 18 for depression or pain, apart from specialist use for bedwetting from age 6 (UK SmPC). The NHS notes specialist use for some types of nerve pain from age 2 (NHS). The US label does not recommend it under 12 (FDA label).

Liver and kidneys: the dose needs care in liver impairment. Kidney failure does not change how the drug is handled, so usual doses can be used (UK SmPC).

Dosage and how to take it

How to take it: usually once a day before bed for pain, because it causes sleepiness. If you still feel drowsy in the morning, taking it earlier in the evening may help. It can be taken with or without food. Swallow tablets whole, because they taste bitter if chewed, and measure liquid with the syringe or spoon provided. If you miss a dose, never take two doses together (NHS).

How long before it works: for pain, sleep may improve straight away. Pain usually starts to ease after 1–2 weeks, but the full effect can take 4–6 weeks, so the NHS advises allowing at least 6 weeks (NHS). For depression, people may feel better after 2–4 weeks, with the full effect at 4–6 weeks. Treatment usually continues for 6 months to a year after recovery (NHS).

How to stop: only with your prescriber. The NHS says the dose is usually reduced "gradually over several weeks, or longer if you've been taking amitriptyline for a long time" (NHS). NICE recommends tapering in steps, each a proportion of the previous dose (for example 50%). Smaller steps are used as the dose gets lower, and liquid forms can help with this. Monitoring during the taper covers both withdrawal symptoms and return of the original condition (NICE NG222). Long-term use for pain or migraine should be reviewed regularly with your doctor (NHS).

Follow the money: who makes it and who funded the evidence

Who made it and who sells it now

• Originator: Merck & Co (USA). FDA approval came on 7 April 1961 as Elavil. Merck co-marketed it with Hoffmann-La Roche (Switzerland) worldwide except the USA, where Merck sold it alone. Roche also held European rights under the name Saroten (López-Muñoz et al., 2022).
• Brand today: the Elavil applications (NDA 012703, 012704) are now in AstraZeneca's name and are listed as discontinued (Drugs@FDA). No company holds a patent-protected amitriptyline product.
• Generic makers: 19 active single-ingredient US generic approvals belong to 13 sponsors, including Accord, Aurobindo, Mylan (Viatris), Sandoz, Sun Pharma, Unichem and Zydus (openFDA). UK licences are held by several generic companies. For example, Brown & Burk UK Ltd holds the licence for the SmPC cited here, revised 28 April 2026 (UK SmPC).
• Revenue: we found no documented sales figure for amitriptyline from any company. As a decades-old generic, it earns little for any single maker. The WHO notes that generic tricyclics have "low acquisition costs" (WHO mhGAP 2023).

Who funded the evidence

• The original 1960s evidence was commissioned by the manufacturer. Merck commissioned Frank Ayd's early clinical work, which treated 130 patients (López-Muñoz et al., 2022). In the depression trial base overall, 78% of trials were funded by pharmaceutical companies. For amitriptyline specifically, older and smaller trials showed larger effects (Cipriani et al., 2018).
• Most modern evidence on low-dose uses is publicly funded. ATLANTIS was funded by the UK NIHR HTA programme (Ford 2023). CHAMP was funded by the US NIH (NINDS and NICHD) (Powers 2017). The low back pain trial was funded by Australia's NHMRC, "which had no role" in the study (Urquhart 2018). The Cochrane pain reviews were supported by NIHR (Moore 2015). The overdose and dementia studies were NIHR-funded (Hawton 2010, Coupland 2019). The CPIC genetics guideline was NIH-funded (Hicks 2017).
• Industry ties appear in the guideline-level reviews, mostly through rival products. Several authors of the NeuPSIG nerve-pain meta-analyses declare fees from companies such as Pfizer, Grünenthal and Lilly. Pfizer (now alongside Viatris) and Lilly are the US label holders for pregabalin (Lyrica) and duloxetine (Cymbalta) respectively (openFDA label data). These drugs compete with amitriptyline for first-line use. These reviews still ranked tricyclics at least equal to those drugs (Soliman 2025, Finnerup 2015). In the fibromyalgia network meta-analysis, two author affiliations are listed as Merck & Co and AbbVie, and conflicts were reported as "none" (Farag 2022).
• What generic status means in practice. No patent holder has a financial reason to fund large new trials. The Cochrane fibromyalgia authors wrote that it is "unlikely that any large randomised trials of amitriptyline will be conducted in fibromyalgia" (Moore 2019). In practice, public funders such as NIHR and NIH have produced most of the high-quality amitriptyline evidence of the last decade.
• Documented regulatory events: in December 2025 the MHRA issued a Class 4 medicines defect notification. Flamingo Pharma UK Ltd's amitriptyline 10 mg, 25 mg and 50 mg tablets had patient leaflets that "do not contain all the required safety information" (MHRA Safety Roundup, December 2025). We found no fraud settlements or data-integrity cases specific to amitriptyline.

Related research

• Stress, anxiety and depression: prevention and treatment guide
• Supplements for stress, anxiety and depression: the evidence
• Sleep: evidence-based prevention guide and sleep supplements evidence
• St John's wort: do not combine it with amitriptyline
• Melatonin, magnesium, L-theanine, saffron for depression and ashwagandha
• Sibling medicine reviews: duloxetine, pregabalin, sertraline, mirtazapine, trazodone and low-dose doxepin

Frequently asked questions

Sources and funding notes

• NHS: Amitriptyline for pain and migraine (about, dosing, side effects, interactions, pregnancy and common-questions pages) — UK government health service; no commercial funding.
• NHS: Amitriptyline for depression (pages last reviewed 28 February 2025) — UK government health service.
• UK Summary of Product Characteristics, Amitriptyline 10 mg film-coated tablets (Brown & Burk UK Ltd), revised 28/04/2026 — written by the licence holder and approved by the MHRA (UK).
• US FDA-approved amitriptyline hydrochloride tablets label (DailyMed; label version 12 June 2024) — manufacturer text reviewed and approved by the FDA (USA).
• Drugs@FDA: Elavil NDA 012704 (AstraZeneca) and openFDA Drugs@FDA dataset — US regulator databases.
• openFDA drug label data (Lyrica, Cymbalta label holders) — US regulator database.
• NICE CG173: Neuropathic pain in adults — UK government-funded guideline body.
• NICE NG193: Chronic pain in over 16s — UK government-funded.
• NICE CG150: Headaches in over 12s (amended 2025) — UK government-funded.
• NICE NG222: Depression in adults (2022) — UK government-funded.
• NICE CG61: Irritable bowel syndrome in adults — UK government-funded.
• WHO mhGAP guideline, 3rd edition (2023) — World Health Organization guideline (international).
• Ford et al., ATLANTIS, Lancet 2023 — UK; NIHR HTA grant 16/162/01; authors declared NIHR grants, and one reported speaker payments from Xytal.
• Wright-Hughes et al., ATLANTIS full report, Health Technology Assessment 2024 — UK; NIHR HTA.
• NIHR Evidence alert on ATLANTIS (2024) — UK; funder's plain-English summary.
• Wright-Hughes et al., post-hoc analysis of ATLANTIS, Gut 2025 — UK; exploratory analysis by the trial team.
• Black et al., Lancet Gastroenterol Hepatol 2020 — UK/international; "Funding: None".
• Ford et al., Am J Gastroenterol 2019 — UK/US/Canada; funding not shown in abstract.
• Cipriani et al., Lancet 2018 — UK/Japan/international; NIHR Oxford Health BRC and JSPS; 409 of 522 trials (78%) industry-funded; several co-authors declare fees from antidepressant makers.
• Moore et al., Amitriptyline for neuropathic pain in adults, Cochrane 2015 — UK; NIHR-funded review programme; no review-related conflicts.
• Moore et al., Amitriptyline for fibromyalgia in adults, Cochrane 2019 — UK; NIHR-funded; no review-related conflicts.
• Moore et al., Overview of Cochrane reviews for fibromyalgia, Rheumatology 2025 — international academic; funding not shown in abstract.
• Farag et al., JAMA Netw Open 2022 — USA; no conflicts reported; two listed affiliations are Merck & Co and AbbVie.
• Soliman et al., NeuPSIG, Lancet Neurol 2025 — international; funded by NeuPSIG and ERA-NET Neuron; multiple authors declare pharmaceutical fees.
• Finnerup et al., Lancet Neurol 2015 — international; NeuPSIG of IASP; multiple authors declare pharmaceutical fees.
• Pringsheim et al., AAN/AHS systematic review, Neurology 2026 — USA/Canada; funding and conflicts not verified from the abstract.
• Powers et al., CHAMP trial, NEJM 2017 — USA; NIH (NINDS, NICHD) grants U01NS076788 and U01NS077108.
• Tao et al., Ann Med 2026 — China; no conflicts reported.
• Talley et al., Gastroenterology 2015 — USA/Australia multicentre; funding not verified from the abstract.
• Urquhart et al., JAMA Intern Med 2018 — Australia; NHMRC-funded, and the funder had no role; no conflicts.
• Everitt et al., Antidepressants for insomnia, Cochrane 2018 — UK; some co-authors declare past industry grants or fees, and the lead author declares none.
• Hawton et al., Br J Psychiatry 2010 — UK; NIHR Programme Grant RP-PG-0606-1247; one author sits on an MHRA advisory group.
• American Geriatrics Society 2023 Beers Criteria — USA; "no sponsor"; a few panel members consult for drug-information or insurer companies, and one member's spouse holds AbbVie and Abbott shares.
• Coupland et al., JAMA Intern Med 2019 — UK; NIHR School for Primary Care Research; two authors report ClinRisk Ltd fees.
• Hicks et al., CPIC guideline for CYP2D6/CYP2C19 and tricyclics, Clin Pharmacol Ther 2017 — USA/international; NIH-funded; some authors consult for genetic-testing firms or report Japanese pharmaceutical support.
• López-Muñoz et al., World J Psychiatry 2022 — Spain; academic history review; nothing to disclose.
• MHRA Drug Safety Update: Antidepressants and risk of fractures — UK regulator.
• MHRA Drug Safety Update: Tapentadol with other medicines — UK regulator.
• MHRA Safety Roundup, December 2025 — UK regulator.

Last reviewed: 26 September 2026. Educational information from Pure City Research, not medical advice. Medicine decisions belong with a qualified prescriber.